查詢結果分析
相關文獻
- Current Antithrombotic Therapy in Cardiac Disease
- Successful Treatment of Patent Ductus Arteriosus in Two Dogs
- 談治療心臟疾病臨床心得
- Blood Lipid Distrbution in Patients with Newly-Diagnosed, Non-Insulin-Dependent Diabetes Mellitus
- 臉部異常、先天性心臟病及胸腺缺損
- Myocardial Contrast Echocardiography and Dobutamine Echocardiography in Predicting Viable Myocardium
- 醫師處方評估及病患用藥指導: 乙種維生素缺乏引起之心臟病變
- Transesophageal Echocardiography of a Patient with Fenestrated Type Atrial Septal Defect
- Transradial Approach for Diagnosis of Cardiovascular Disease in Taiwanese Patients: Catheter Selection, Feasibility, Complications and Application
- 核醫心臟檢查偵測冠狀動脈心臟病近況
頁籤選單縮合
題名 | Current Antithrombotic Therapy in Cardiac Disease=心臟病抗血栓藥物之最新治療 |
---|---|
作者 | 丁予安; |
期刊 | 醫學研究 |
出版日期 | 19881100 |
卷期 | 9:3 1988.11[民77.11] |
頁次 | 頁161-173 |
分類號 | 415.31 |
語文 | eng |
關鍵詞 | 心臟病; 抗血栓藥物; |
中文摘要 | 防止血栓及血栓治療許多心臟病中最重要的一部份,它能降低此類血栓併發症之死亡率及罹患率。近年來研究均證實血小板凝集及血栓形成在冠狀動脈心臟病、心臟病腔室疾病、瓣膜性心臟病、人工心臟瓣膜、以及冠狀動脈擴張術後再狹窄及阻塞均扮演著非常重要的角色。許多抗血栓藥物雖然很新、有效但迄今仍未完美,臨床上若使用時機適當、劑量正確、合適的適應症以及治療適切的時間均被證實有效。血栓栓塞高危險羣患者需要抗血栓藥物合併抗血小板凝集劑治療;中度危險羣患者需要抗血栓藥物治療;低危險羣患者只需抗血小板凝集劑治療。更新、更有效的抗血栓藥物現正發展試驗中,希望不久的未來,血栓栓塞併發症能大量地減少,甚至於完全防止。 |
英文摘要 | The prevention of thromboisis and emboli is an important aspect in the therapy of many heart diseases and can greatly reduce the incidence of mortality and morbidity. Recent evidence strongly suggests the role of platelet aggregation and thrombosis in the progression of coronary artery disease, disease of the cardiac chambers, valvular heart disease, prosthetic heart valves, and restenosis and occlusion post coronary intervention. Many antithrombotic drugs, some quite new and potent but none still perfect, and presently in clinical use and have proven to be effective when used at the right time, in the correct dosage, for the indicated conditions and risks, and for the right duration. High risk conditions for thromboembolism warrant therapy with a combination of an anticoagulant with a platelet inhibitor; medium risk conditions necessitate treatment with anticoagulant alone, and low risk conditions may require only platelet inhibitors. Newer and more powerful antithrombotic drugs are now being developed and tested with the hope that thromboembolic complications can be greatly reduced or fully prevented in the near future. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。